This article is more than 5 years old. Information may no longer be current.

EyeGate reports $2.38 million loss in first quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a net loss of $2.38 million in the first 3 months of 2018 compared with $2.92 million in the same period of 2017, according to a press release.

Revenue for the quarter totaled $1.096 million compared with $0.185 million in 2017’s first quarter.

Research and development costs increased from $1.815 million in the first 3 months of 2017 to $2.521 million in this year’s first quarter, which was attributed to activity related to anterior uveitis treatment candidate EGP-437.

General and administrative expenses for the quarter decreased from $1.289 million in 2017 to $0.954 million in 2018.

The company reported cash and cash equivalents of $3.65 million as of March 31.